JP6964593B2 - ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン - Google Patents
ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン Download PDFInfo
- Publication number
- JP6964593B2 JP6964593B2 JP2018540013A JP2018540013A JP6964593B2 JP 6964593 B2 JP6964593 B2 JP 6964593B2 JP 2018540013 A JP2018540013 A JP 2018540013A JP 2018540013 A JP2018540013 A JP 2018540013A JP 6964593 B2 JP6964593 B2 JP 6964593B2
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- administered
- day
- compound
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- RYDIHHBIRNPQNA-UHFFFAOYSA-O C[NH+](CC1)CCN1C(c1c(cc2)[o]c2c1C(C[O-])=O)=O Chemical compound C[NH+](CC1)CCN1C(c1c(cc2)[o]c2c1C(C[O-])=O)=O RYDIHHBIRNPQNA-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662287858P | 2016-01-27 | 2016-01-27 | |
| US62/287,858 | 2016-01-27 | ||
| PCT/US2017/015237 WO2017132445A1 (en) | 2016-01-27 | 2017-01-27 | Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507134A JP2019507134A (ja) | 2019-03-14 |
| JP2019507134A5 JP2019507134A5 (https=) | 2020-03-12 |
| JP6964593B2 true JP6964593B2 (ja) | 2021-11-10 |
Family
ID=59398691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540013A Expired - Fee Related JP6964593B2 (ja) | 2016-01-27 | 2017-01-27 | ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20190111053A1 (https=) |
| EP (1) | EP3407887B1 (https=) |
| JP (1) | JP6964593B2 (https=) |
| CN (1) | CN109475543A (https=) |
| CA (1) | CA3051828A1 (https=) |
| WO (1) | WO2017132445A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160004299A (ko) | 2013-04-09 | 2016-01-12 | 릭스트 바이오테크놀로지, 인코포레이티드 | 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형 |
| ES2985668T3 (es) | 2015-05-15 | 2024-11-06 | Lixte Biotechnology Inc | Profármacos de oxabicicloheptano para uso en el tratamiento del cáncer |
| WO2018027144A1 (en) * | 2016-08-04 | 2018-02-08 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Companion diagnostic for combination lenalidomide and erythropoietin treatment |
| EP4324477A3 (en) | 2016-12-08 | 2024-05-22 | Lixte Biotechnology, Inc. | Oxabicycloheptanes for modulation of immune response |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080267947A1 (en) | 2006-09-07 | 2008-10-30 | Cirrito Thomas P | Cancer therapy with cantharidin and cantharidin analogs |
| BRPI0806365B8 (pt) | 2007-02-06 | 2021-05-25 | Lixte Biotechnology Holdings Inc | composto, uso do composto, composição farmacêutica e uso da composição farmacêutica |
| KR20160004299A (ko) * | 2013-04-09 | 2016-01-12 | 릭스트 바이오테크놀로지, 인코포레이티드 | 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형 |
| EP3171870B1 (en) * | 2014-07-24 | 2021-10-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes |
| WO2016040877A1 (en) * | 2014-09-12 | 2016-03-17 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
-
2017
- 2017-01-27 WO PCT/US2017/015237 patent/WO2017132445A1/en not_active Ceased
- 2017-01-27 CA CA3051828A patent/CA3051828A1/en active Pending
- 2017-01-27 CN CN201780019895.5A patent/CN109475543A/zh active Pending
- 2017-01-27 JP JP2018540013A patent/JP6964593B2/ja not_active Expired - Fee Related
- 2017-01-27 US US16/072,963 patent/US20190111053A1/en not_active Abandoned
- 2017-01-27 EP EP17744934.5A patent/EP3407887B1/en not_active Not-in-force
-
2022
- 2022-03-04 US US17/687,231 patent/US20220323433A2/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109475543A (zh) | 2019-03-15 |
| US20220184066A1 (en) | 2022-06-16 |
| JP2019507134A (ja) | 2019-03-14 |
| EP3407887A4 (en) | 2019-09-25 |
| WO2017132445A1 (en) | 2017-08-03 |
| US20190111053A1 (en) | 2019-04-18 |
| EP3407887B1 (en) | 2021-09-01 |
| CA3051828A1 (en) | 2017-08-03 |
| US20220323433A2 (en) | 2022-10-13 |
| EP3407887A1 (en) | 2018-12-05 |
| WO2017132445A8 (en) | 2018-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220323433A2 (en) | Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor | |
| US11337983B2 (en) | Dactinomycin compositions and methods for the treatment of acute myeloid leukemia | |
| CN103501785B (zh) | 用于治疗脑肿瘤的csf-1r抑制剂 | |
| JP6833816B2 (ja) | 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ） | |
| KR102613106B1 (ko) | Ｂ―세포 악성종양의 치료를 위한 세르둘라티닙 | |
| JP2021517582A (ja) | 細胞外ヒストンによって媒介される病理を処置及び予防するための化合物 | |
| WO2016168451A1 (en) | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment | |
| CN118215481A (zh) | 晚期和/或转移性Trop-2过表达癌症患者的联合治疗 | |
| WO2022090443A1 (en) | Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor | |
| US12521425B2 (en) | Method of liver cancer treatment with safranal-based formulations | |
| EP4095137A1 (en) | Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma | |
| CN113260361A (zh) | 使用免疫调节治疗癌症的新型方法 | |
| JP2024519342A (ja) | 自己免疫性、同種免疫性、炎症性、及びミトコンドリア性の状態を治療するための組成物、ならびにその使用 | |
| HK40000014B (en) | Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor | |
| CN116492342B (zh) | 氯喹或羟氯喹在制备治疗尼洛替尼肾脏毒副作用药物中的应用 | |
| US11918550B2 (en) | Sensitization of cancer cells to differentiation therapy with mitochondrial uncoupler niclosamide ethanolamine | |
| CA3217214A1 (en) | Methods of treatment with n-((r)-1-(3-chloropyridin-2-yl)- 2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1- oxoisoindoline-5-carboxamide | |
| WO2025241125A1 (zh) | 度洛西汀及化疗药物用于制备用于治疗或预防癌症的医药组成物的用途 | |
| WO2022175858A1 (en) | Dicarboximide derivative for use in cancer treatment | |
| WO2026012350A1 (zh) | 色烯酮类化合物的应用 | |
| HK40092504A (zh) | 治疗癌症的bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物 | |
| HK40085748A (en) | Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma | |
| JP2020132626A (ja) | サフラナール製剤によるｃｄｃ２５ｂの抑制および阻害 | |
| HK40003387B (zh) | 用於治疗胰腺癌的治疗性组合物 | |
| JP2019112389A (ja) | 膵臓癌を処置するための治療用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200127 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200127 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210317 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210824 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210922 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211019 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6964593 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |